The General Court of the European Union has broadly upheld the fine imposed by the European Commission on AstraZeneca for abuse of a dominant position by blocking or delaying generic versions of its proton pump inhibitor, the anti-ulcer drug Losec (omeprazole)1. The move is expected to give support to the commission in its pursuit of antitrust actions against pharmaceutical companies; pharmaceutical industry federation EFPIA said the ruling could have a "chilling effect" on innovation2...
Please login to read the full article.
